Revance Therapeutics reported $64.09M in Selling and Administration Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.3B 174M
ALKERMES ALKS:US USD 152.78M 2.4M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Cara Therapeutics CARA:US USD 6.88M 658K
Coherus Biosciences CHRS:US USD 44.83M 6.44M
Eli Lilly And LLY:US USD 1.61B 10.9M
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
Horizon Pharma HZNP:US USD 397.56M 658K
JAZZ PHA JAZZ:US USD 317.68M 7.99M
Johnson & Johnson JNJ:US USD 6.51B 423M
Merk MRK:US USD 2.47B 13M
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Pacira Pharmaceuticals PCRX:US USD 61.28M 3.72M
Procter & Gamble PG:US USD 5.09B 264M
Revance Therapeutics RVNC:US USD 64.09M 17.91M
Supernus Pharmaceuticals SUPN:US USD 224.63M 124.15M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M